Direkt zum Inhalt | Direkt zur Navigation

Benutzerspezifische Werkzeuge

Sie sind hier: Startseite / Forschung / Publikationen / Fachjournalartikel



  • Altin SV, Stock S. Impact of health literacy, accessibility and coordination of care on patient's satisfaction with primary care in Germany. BMC family practice. 2015;16(1):148.
  • Danner M, Vennedey V, Hiligsmann M, Fauser S, Stock S. Focus Groups in Elderly Ophthalmologic Patients: Setting the Stage for Quantitative Preference Elicitation. The patient. 2015 Mar 1. [epub ahead of print]
  • Kautz-Freimuth S, Redaelli M, Samel C, Civello D, Altin SV, Stock S. Parental views on acute otitis media (AOM) and its therapy in children - results of an exploratory survey in German childcare facilities. BMC pediatrics. 2015;15(1):199.
  • Müller D, Fischer K, Kaiser P, Eichhorst B, Walshe R, Reiser M, Kellermann L, Borsi L, Civello D, Mensch A, Bahlo J, Hallek M, Stock S, Fingerle-Rowson G. Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia. Leukemia & lymphoma. 2015 Nov 20:1-10.
  • Stock S, Tebest R, Westermann K, Samel C, Strohbücker B, Stosch C, et al. Implementation of an innovative hands-on training to improve adherence to hygiene rules: A feasibility Study. Nurse Education Today. 2015.
  • Tebest R, Mehnert T, Nordmann H, Stock S. "Pflegestutzpunkte": Care Support Centers in Germany. Where are We Heading? Results of the Evaluation of all 48 Care Support Centers in Baden-Wurttemberg. Gesundheitswesen. 2015 Nov 9. [epub ahead of print]
  • Simon, B, Sawicki P. Quality improvement in chronic care delivery for patients with arterial hypertension through Group Medical Visits: Patient acceptance and attendance in the German pilot project. Quality in Primary Care. 2015;23(2):106-12.
  • van Mastrigt GA, Paulus AT, Aarts MJ, Evers SM, Alayli-Goebbels AF. A qualitative study on the views of experts regarding the incorporation of non-health outcomes into the economic evaluations of public health interventions. BMC public health. 2015;15(1):954.
  • Stollenwerk B, Welchowski T, Vogl M, Stock S. Cost-of-illness studies based on massive data: a prevalence-based, top-down regression approach. The European journal of health economics : HEPAC : health economics in prevention and care. 2015 Feb 4.
  • Stock S, Altin S, Palmowski S, Berger B, Passon A. Patients' advocates and counselors: Perceived needs in education and training. Patient education and counseling. 2015 Jun 23.
  • Simon B, Sawicki PT. Group Medical Visits – Patient Acceptance and Attendance of the New Primary Care Model. Z Allg Med. 2015;10:416-21.
  • Schencking M, Sonnichsen A, Bassuner S, Redaelli M. The CUPCIG (CAM-Use in Primary Care in Germany) Study:Part I-Pain. Study Protocol of a Pilot-trial to Assess Feasibility, Acceptability and Perceived Effectiveness of CAM in Pain Disorders in Primary Care. Forschende Komplementarmedizin. 2015;22(3):195-200.
  • Mensch A, Stock S, Stollenwerk B, Muller D. Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation. PharmacoEconomics. 2015 Mar;33(3):271-83.
  • Meffert C, Gaertner J, Seibel K, Jors K, Bardenheuer H, Buchheidt D, et al. Early Palliative Care-Health services research and implementation of sustainable changes: the study protocol of the EVI project. BMC cancer. 2015;15:443.
  • Hertle D, Stock S. [Commonwealth Fund Survey 2012: Survey of Primary Care Doctors in 11 Countries: Use of Health Information Technology and Important Aspects of Care]. Gesundheitswesen. 2015 Sep;77(8-09):542-9.
  • Gaertner J, Siemens W, Antes G, Meerpohl JJ, Xander C, Schwarzer G, et al. Specialist palliative care services for adults with advanced, incurable illness in hospital, hospice, or community settings--protocol for a systematic review. Systematic reviews. 2015;4:123.
  • Chong E, Alayli-Goebbels AF, Webel-Edgar L, Muir S, Manson H. Advancing Telephone Focus Groups Method through the use of webinar: Methodological reflections on evaluating Ontario, Canada’s Healthy Babies Healthy Children Program. Global Qualitative Nursing Research. 2015.
  • Benning TM, Alayli-Goebbels AF, Aarts MJ, Stolk E, de Wit GA, Prenger R, et al. Exploring Outcomes to Consider in Economic Evaluations of Health Promotion Programs: What Broader Non-Health Outcomes Matter Most? BMC health services research. 2015;15:266.
  • Altin SV, Lorrek K, Stock S. Development and validation of a brief screener to measure the Health Literacy Responsiveness of Primary Care Practices (HLPC). BMC family practice. 2015;16:122.
  • Altin SV, Halbach S, Ernstmann N, Stock S. Wie können krebsspezifische Gesundheitskompetenzen gemessen werden? – Ein systematischer Review über die Qualität vorhandener Messinstrumente. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen. 2015.
  • Altin S, Passon A, Kautz-Freimuth S, Berger B, Stock S. A qualitative study on barriers to evidence-based practice in patient counseling and advocacy in Germany. BMC health services research. 2015;15:317.



  • Schmiemann G, Simon, B, Mozygemba K. First Experience with Group Medical Appointments in a Family Practice. Z Allg Med. 2014;2:85-7.
  • Simon, B, Sawicki P. Group Medical Visits – a Novel Model of Care in the Family Physician’s Office?; in ZFA Zeitschrift für Allgemeinmedizin 2014; 1: 20-25.
  • Zyriax BC, Letsch B, Stock S, Windler E. DELIGHT (delay of impaired glucose tolerance by a healthy lifestyle trial) - a feasibility study on implementing a program of sustainable diabetes prevention in German companies. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. 2014 Jan;122(1):20-6.
  • Stollenwerk B, Waldeyer R, Klein-Meding C, Muller D, Stock S. Cost effectiveness of external hip protectors in the hospital setting: a modeling study. Nursing economic$. 2014 Mar-Apr;32(2):89-98.
  • Stollenwerk B, Lhachimi SK, Briggs A, Fenwick E, Caro JJ, Siebert U, et al. Communicating the parameter uncertany in the IQWiG efficiency frontier to decision-makers. Health economics. 2014 Mar 4.
  • Stock S, Redaelli M, Simic D, Siegel M, Henschel F. Risk factors for the prescription of potentially inappropriate medication (PIM) in the elderly : An analysis of sickness fund routine claims data from Germany. Wiener klinische Wochenschrift. 2014 Oct;126(19-20):604-12.
  • Stock S, Pitcavage JM, Simic D, Altin S, Graf C, Feng W, et al. Chronic care model strategies in the United States and Germany deliver patient-centered, high-quality diabetes care. Health affairs. 2014 Sep;33(9):1540-8.
  • Stock S, Danner M. [Does the elicitation of stakeholder attitudes and preferences add valuable information to small-area analyses? A health policy perspective]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2014 Feb;57(2):188-96.
  • Pendzialek JB, Simic D, Stock S. Differences in price elasticities of demand for health insurance: a systematic review. The European journal of health economics : HEPAC : health economics in prevention and care. 2014 Nov 15.
  • Muller D, Pullenayegum E, Gandjour A. Impact of small study bias on cost-effectiveness acceptability curves and value of information analyses. The European journal of health economics : HEPAC : health economics in prevention and care. 2014 May 20.
  • Muller D, Borsi L, Stracke C, Stock S, Stollenwerk B. Cost-effectiveness of a multifactorial fracture prevention program for elderly people admitted to nursing homes. The European journal of health economics : HEPAC : health economics in prevention and care. 2014 May 13.
  • Mayer-Berger W, Simic D, Mahmoodzad J, Burtscher R, Kohlmeyer M, Schwitalla B, et al. Efficacy of a long-term secondary prevention programme following inpatient cardiovascular rehabilitation on risk and health-related quality of life in a low-education cohort: a randomized controlled study. European journal of preventive cardiology. 2014 Feb;21(2):145-52.
  • Kautz-Freimuth S, Tebest R, Schmidt A, Salem M, Civello D, Flinkerbusch M, et al. Development, implementation and evaluation of a multifaceted curriculum for an interprofessional continuing training program in oncology. Oncology Research and Treatment. 2014 Oct;37:173-.
  • Hirsch O, Strauch K, Held H, Redaelli M, Chenot JF, Leonhardt C, et al. Low back pain patient subgroups in primary care: pain characteristics, psychosocial determinants, and health care utilization. The Clinical journal of pain. 2014 Dec;30(12):1023-32.
  • Heinzel A, Muller D, Behrendt FF, Giovanella L, Mottaghy FM, Verburg FA. Thyroid nodules with indeterminate cytology: molecular imaging with (9)(9)mTc-methoxyisobutylisonitrile (MIBI) is more cost-effective than the Afirma gene expression classifier. European journal of nuclear medicine and molecular imaging. 2014 Aug;41(8):1497-500.
  • Gandjour A, Muller D. Ethical objections against including life-extension costs in cost-effectiveness analysis: a consistent approach. Applied health economics and health policy. 2014 Oct;12(5):471-6.
  • Droege KM, Caramoy A, Kersten A, Luberichs-Fauser J, Zilkens K, Muller D, et al. Patient preference of ranibizumab treatment regimen for neovascular age-related macular degeneration - monthly injections versus pro re nata. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2014 Jan;252(1):31-4.
  • Burnus M, Benner V, Becker L, Muller D, Stock S. Entwicklung eines Instruments zur Bedarfsermittlung und zum Monitoring im Betrieblichen Gesundheitsmanagement (BGM) eines Versicherungskonzerns. Versicherungsmedizin. 2014;66(22):16.
  • Berghaus S, Muller D, Gandjour A, Civello D, Stock S. Osteoporosis in German men: a cost-of-illness study. Expert review of pharmacoeconomics & outcomes research. 2014 Dec 11:1-7.
  • Altin SV, Finke I, Kautz-Freimuth S, Stock S. The evolution of health literacy assessment tools: a systematic review. BMC public health. 2014 Nov 24;14(1):1207.
  • Altin S, Tebest R, Kautz-Freimuth S, Redaelli M, Stock S. Barriers in the implementation of interprofessional continuing education programs - a qualitative study from Germany. BMC medical education. 2014;14(1):227.



    • Arnolds S, Heckermann S, Koch C, Heissmann N, Sawicki PT; How do patients' preferences compare to the present spectrum of diabetes research? Exp Clin Endocrinol Diabetes. 2013;121(1): 60-3
    • Gaertner J, Drabik A, Marschall U, Schlesiger G, Voltz R, Stock S; Inpatient Palliative Care: A nationwide analysis. Health Policy. 2013;109(3): 311-8 (IF: 1.725)
    • Siegel M, Luengen M, Stock S; On age-specific variations in income-related inequalities in diabetes, hypertension and obesity. Int J Public Health. 2013;58(1): 33-41 (IF: 1.966)
    • Passon AM, Drabik A, Sawicki PT; Quality scores do not predict discrepant statistical significances among meta-analyses on different targets of glycemic control in type 2 diabetes. J Clin Epidemiol. 2013;66(12): 1356-66
    • Heinzel A, Müller D, Langen KJ, Blaum M, Verburg FA, Mottaghy FM, Galldiks N; The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis. J Nucl Med. 2013;54(8): 1217-22
    • Gibbert J, Müller D, Fauser S, Stock S; Cost of illness of age-related macular degeneration. Systematic review on the development of a costs diary. Ophthalmologe. 2013;110(6): 528-36
    • Gandjour A; Validation of models that estimate the cost-effectiveness of improving patient adherence. Value Health. 2013;16(8): 1170-1 (IF:2.891)
    • Stollenwerk B, Le L, Zindel S, Muller D, Klug F, Stock S; A Societal Perspective Cost-Utility Analysis of Rivaroxaban Compared with Enoxaparin Sodium in Patients Undergoing Total Hip or Total Knee Replacement Surgery. Value Health. 2013;16(7): A530-A530 (IF: 2.891) (Meeting Abstract)









      • Gerber A, Kohaupt I, Lauterbach KW, Buescher G, Stock S, Lungen M. Quantification and classification of errors associated with hand-repackaging of medications in long-term care facilities in Germany. Am J Geriatr Pharmacother. 2008;6(4): 212-9.
      • Feenstra TL, van Baal PH, Gandjour A, Brouwer WB. Future costs in economic evaluation A comment on Lee. J Health Econ. 2008.
      • Gandjour A. What drives U. S. competitiveness in mathematics and science? Educational Studies 2008;34(4):269-270.
      • Graf C, Koch B, Falkowski G, Jouck S, Christ H, Staudenmaier K, Tokarski W, Gerber A, Predel HG, Dordel S. School-based prevention: effects on obesity and physical performance after 4 years. J Sports Sci. 2008;26(10): 987-94.
      • Gandjour A. Assessing the value of a future study. Pharmacoeconomics. 2008;26(10): 891-2. Gandjour A. Loss aversion and cost effectiveness of healthcare programmes. Pharmacoeconomics. 2008;26(11): 895-8.
      • Gandjour A. Aging diseases - do they prevent preventive health care from saving costs? Health Econ. 2008.
      • Rosta J, Gerber A. Job satisfaction of hospital doctors. Results of a study of a national sample of hospital doctors in Germany. Gesundheitswesen. 2008;70(8-9): 519-24.
      • Gandjour A. Incorporating feelings related to the uncertainty about future health in utility measurement. Health Econ. 2008;17(10): 1207-13. Gandjour A. Informing patients of their coronary risk. Arch Intern Med. 2008;168(15): 1719.
      • Gandjour A, Ihle P, Schubert I. Impact of demographic changes on health care expenditure in Germany: an analysis considering the expenditures of decedents. Gesundheitswesen. 2008;70(2): 77-80.
      • Stock S, Stollenwerk B, Klever-Deichert G, Redaelli M, Büscher G, Graf C, Möhlendick K, Mai J, Gerber A, Lüngen M, Lauterbach KW. Preliminary analysis of short-term financial implications of a prevention bonus program: first results from the German Statutory Health Insurance. Int J Public Health. 2008;53(2): 78-86.
      • Gandjour A. The ethics of non-inferiority trials. Lancet. 2008;371(9616): 895; author reply 896-7.
      • Lüngen M, Gerber A, Rupprecht C, Lauterbach KW. Efficiency of computer-based documentation in long-term care--preliminary project. Pflege Z. 2008;61(6): 334-9.
      • Mueller D, Weyler E, Gandjour A. Cost effectiveness of the German screen-and-treat strategy for postmenopausal osteoporosis. Pharmacoeconomics. 2008;26(6): 513-36.
      • Plamper E, Meinhardt M. Participation of patient advocates in decision-making on the regulation of medical services in Germany. The perspective of patient advocates in the Federal Joint Committee and in the Federal Office of Quality Assurance. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2008;51(1): 81-8.
      • Seifert H, Wisplinghoff H, Kaasch A, Achilles K, Langhorst A, Peyerl-Hoffmann G, Woehrmann A, Fätkenheuer G, Salzberger B, Kern WV. Epidemiology, course and prognosis of Staphylococcus aureus bacteremia--Preliminary results from the INSTINCT (INvasive STaphylococcus aureus INfection CohorT) cohort] Dtsch Med Wochenschr. 2008;133(8): 340-5.
      • Lungen M, Stollenwerk B, Messner P, Lauterbach KW, Gerber A. Waiting times for elective treatments according to insurance status: A randomized empirical study in Germany. Int J Equity Health. 2008;7: 1. Gandjour A. Mutual dependency between capabilities and functionings in Amartya Sen's capability approach. Soc Choice Welfare. 2008;31(2): 345-350.
      • Gandjour A, Weyler EJ. Cost-Effectiveness of Preventing Hip Fractures by Hip Protectors in Elderly Institutionalized Residents in Germany. Value Health. 2008;11(7): 1088-1095.
      • Stock SA, Stollenwerk B, Redaelli M, Civello D, Lauterbach KW. Sex Differences in Treatment Patterns of Six Chronic Diseases: An Analysis from the German Statutory Health Insurance. J Womens Health (Larchmt). 2008.



      • Gandjour A. Is it rational to pursue utilitarianism? Ethical Perspectives 2007;2:139-58. Rosta J, Gerber A. Excessive working hours and health complaints among hospital physicians: a study based on a national sample of hospital physicians in Germany. GMS Ger Med Sci. 2007;5:Doc09.
      • Icks A, Rathmann W, Haastert B, Gandjour A, Holle R, John J, Giani G. Clinical and cost-effectiveness of primary prevention of Type 2 diabetes in a 'real world' routine healthcare setting: model based on the KORA Survey 2000. Diabet Med. 24(5). 2007:473-80.
      • Gandjour A. Changing the organization of health care. JAMA. 298(3). 2007:286.
      • Weyler EJ, Gandjour A. Socioeconomic burden of hip fractures in Germany. Gesundheitswesen. 2007;69(11): 601-6.
      • Gandjour A, Stock S. A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness. Health Policy. 2007.
      • Stock SA, Redaelli M, Lauterbach KW. Disease management and health care reforms in Germany - does more competition lead to less solidarity? Health Policy. 80(1). 2007:86-96.
      • Gerber A, Hentzelt F, Lauterbach KW. Can evidence-based medicine implicitly rely on current concepts of disease or does it have to develop its own definition?. J Med Ethics. 33(7). 2007:394-9.
      • Stoffel MP, Haverkamp H, Kromminga A, Lauterbach KW, Baldamus CA. Prevalence of anti-erythropoietin antibodies in hemodialysis patients without clinical signs of pure red cell aplasia. Comparison between hypo- and normoresponsive patients treated with epoetins for renal anemia. Nephron Clin Pract. 105(2). 2007:c90-8.
      • Gandjour A. Substantial treatment overuse in the United States? Value Health. 10(3). 2007:221. Lungen M, Gerber A. Comment on "Where's the value in health care"? Value Health. 10(2). 2007:170.
      • Schräder P, Rath T. Volume-outcome-relationship in total hip replacement-literature review and model calculation of the health care situation. Z Orthop Unfall. 145(3). 2007:281-90.



      • Gandjour A. Survivor costs in cost-effectiveness analysis.. Ann Intern Med. 144(7). 2006:534-5.
      • Plamper E, Klever Deichert G, Lauterbach KW. Effects of tobacco tax increase on cigarette consumption and the impact on health policy. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 49(7). 2006:660-4.
      • Stock SAK, Redaelli M, Lauterbach KW. Population-based disease management in the German statutory health insurance - Implementation and preliminary results. DIS MANAG HEALTH OUT. 14(1). 2006:5-12.
      • Stock SA, Redaelli M, Wendland G, Civello D, Lauterbach KW. Diabetes-prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in Germany. Diabet Med. 23(3). 2006:299-305.
      • Icks A, Rathmann W, Haastert B, Gandjour A, Holle R, John J, Giani G. Clinical and cost-effectiveness of primary prevention of type 2 diabetes in a routine health care setting: Model based on the KORA Survey 2000. Diabetologia. 49 Suppl. 2006:202-202.
      • Gerber A, Evers T, Haverkamp H, Lauterbach KW. Cost-benefit analysis of a plant sterol containing low-fat margarine for cholesterol reduction. Eur J Health Econ. 7(4). 2006:247-54.
      • Stock S, Redaelli M, Lauterbach KW. The influence of the labor market on German health care reforms. Health Aff (Millwood). 25(4). 2006:1143-52.
      • Gandjour A, Weyler EJ. Cost-effectiveness of referrals to high-volume hospitals: an analysis based on a probabilistic Markov model for hip fracture surgeries. Health Care Manag Sci. 9(4). 2006:359-69.
      • Gandjour A. Consumption costs and earnings during added years of life - a reply to Nyman. Health Econ. 15(3). 2006:315-7, 319-22.
      • Ruepp K, Stollenwerk B, Brunner H. Pharmacoeconomic evaluation of antifungal prophylaxis in neutropenic patients. Int J Med Microbiol. 296 Suppl. 2006:162-162.
      • Gerber A. Telephone triage in pediatrics - Justified only in cost economisation? Response. Monatsschr Kinderheilkd. 154(4). 2006:376-377.



      • Gandjour A, Greb J, Bomsdorf E, Wilhelm Lauterbach K. Impact of demographic changes on healthcare expenditures and funding in the EU. Appl Health Econ Health Policy. 4(1). 2005:1-4.
      • Stock S, Redaelli M, Luengen M, Wendland G, Civello D, Lauterbach KW. Asthma: prevalence and cost of illness. Eur Respir J. 25(1). 2005:47-53.
      • Gerber A, Lauterbach KW. Evidence-based medicine: why do opponents and proponents use the same arguments?. Health Care Anal. 13(1). 2005:59-71.
      • Gandjour A, Kerschbaum T, Reis A, Lauterbach KW. Technology assessment in dentistry: a comparison of the longevity and cost-effectiveness of inlays. Int J Technol Assess Health Care. 21(3). 2005:319-25.
      • Gandjour A, Lauterbach KW. Does prevention save costs? Considering deferral of the expensive last year of life. J Health Econ. 24(4). 2005:715-24.
      • Gandjour A, Lauterbach KW. How much does it cost to change the behavior of health professionals? A mathematical model and an application to academic detailing. Med Decis Making. 25(3). 2005:341-7.
      • Gerber A, Lungen M, Lauterbach KW. Evidence-based medicine is rooted in Protestant exegesis. Med Hypotheses. 64(5). 2005:1034-8.
      • Gandjour A, Lauterbach KW. When is it worth reducing overuse of health care services? The example of prescribing expensive antihypertensives. Med Klin (Munich). 100(9). 2005:535-41.
      • Scheibler F, Stoffel MP, Barth C, Kuch C, Steffen P, Baldamus CA, Pfaff H. Shared decision-making as a new quality indicator in nephrology: a nationwide survey in Germany. Med Klin (Munich). 100(4). 2005:193-9.
      • Gerber A, Lauterbach KW. Pediatric telephone triage and advice system. Justified only if saving costs?. Monatsschr Kinderheilkd. 153(11). 2005:1089-1100.
      • Kuch C, Stoffel MP, Scheibler F, Barth C, Pfaff H. Shared-decision making in ESRD: Data from QiN on control preference of patients. Nephrol Dial Transplant. 2005;20 Suppl. 2005:V326-V326.
      • Stoffel MP, Scheibler F, Baldamus CA, Barth C. Haemodialysis - clinical/miscellaneous 2. Nephrol Dial Transplant. 20 Suppl 5. 2005:v322-v331.
      • Stoffel MP, Baldamus CA, Barth C. K/DOQI-targets of mineral metabolism in QiN compared to DOPPS. Nephrol Dial Transplant. 20 Suppl. 2005:V97-V97.
      • Gandjour A, Telzerow A, Lauterbach KW. European comparison of costs and quality in the treatment of acute back pain. Spine. 30(8). 2005:969-75.
      • Lauterbach KW, Gerber A, Klever-Deichert G, Stollenwerk B. Cost-effectiveness of prevention of coronary disease in Germany. Z Kardiol. 94 Suppl 3. 2005:100-4.



      • Lüngen M, Lauterbach KW. Health policy guidelines for ambulatory and brief inpatient surgery. Backgrounds, facts and possible future solutions. Chirurg. 75(2). 2004:113-9.
      • Stoffel MP, Barth C, Lauterbach KW, Baldamus CA. Evidence-based medical quality management in dialysis--Part II: Improvement of hemodialysis adequacy. Clin Nephrol. 62(3). 2004:219-25.
      • Stoffel MP, Barth C, Lauterbach KW, Baldamus CA. Evidence-based medical quality management in dialysis--Part I: Routine implementation of QiN, a German quality management system. Clin Nephrol. 62(3). 2004:208-18.
      • Icks A, Haastert B, Gandjour A, John J, Löwel H, Holle R, Giani G, Rathmann W, KORA Study. Cost-effectiveness analysis of different screening procedures for type 2 diabetes: the KORA Survey 2000. Diabetes Care. 27(9). 2004:2120-8.
      • Lüngen M, Stock S, Krauth C, Gerhardus A, Brandes I, Potthoff P, Müller U, Schmitz H, Klostermann B, Steinbach T, Schwartz FW, Lauterbach KW. Performance and costs of outpatient clinics of university hospitals for medical care, teaching, research activities. Dtsch Med Wochenschr. 129(45). 2004:2399-404.
      • Graf C, Koch B, Dordel S, Schindler-Marlow S, Icks A, Schüller A, Bjarnason- Wehrens B, Tokarski W, Predel HG. Physical activity, leisure habits and obesity in first-grade children. Eur J Cardiovasc Prev Rehabil. 11(4). 2004:284-90.
      • Hoffmann T, Brunner H. Model for simulation of HIV/AIDS and cost-effectiveness of preventing non-tuberculous mycobacterial (MAC)-disease. Eur J Health Econ. 5(2). 2004:129-35.
      • Lungen M, Dredge B, Rose A, Roebuck C, Plamper E, Lauterbach K, Working Group. Using diagnosis-related groups. The situation in the United Kingdom National Health Service and in Germany. Eur J Health Econ. 5(4). 2004:287-9.
      • Hauner H, Meier M, Wendland G, Kurscheid T, Lauterbach K, Study Group SA, SAT Study. Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study. Exp Clin Endocrinol Diabetes. 112(4). 2004:201-7.
      • Icks A, Rosenbauer J, Haastert B, Rathmann W, Grabert M, Gandjour A, Giani G, Holl RW. Direct costs of pediatric diabetes care in Germany and their predictors. Exp Clin Endocrinol Diabetes. 112(6). 2004:302-9.
      • Gandjour A, Telzerow A, Lauterbach KW, INTERCARE International Investigators. Costs and quality in the treatment of acute depression in primary care: a comparison between England, Germany and Switzerland. Int Clin Psychopharmacol. 19(4). 2004:201-8.
      • Icks A, Rosenbauer J, Rathmann W, Haastert B, Gandjour A, Giani G. Direct costs of care in germany for children and adolescents with diabetes mellitus in the early course after onset. J Pediatr Endocrinol Metab. 17(11). 2004:1551-9.
      • Gandjour A. Modifiable behavioral factors as causes of death. JAMA. 291(24). 2004:2941.
      • Gandjour A. Educational epidemiology.. JAMA.. 292(24). 2004:2969. Gandjour A, Lauterbach KW. At what time is a reduction of medical under- or overtreatment sensible? Treatment of acute depression as an example. Psychiatr Prax. 31(3). 2004:157-62.
      • Gandjour A, Neumann I, Lauterbach KW. Appropriateness of invasive cardiovascular interventions in German hospitals (2000-2001): an evaluation using the RAND appropriateness criteria. Thorac Cardiovasc Surg. 52(6). 2004:365-71.
      • Kuehne FC, Stoffel MP, Barth C, Baldamus CA. When should erythropoietin (EPO) be replaced by packed red blood celltransfusion (TR) in hemodialysis (HD) patients?. Value Health. 7 Suppl. S(6). 2004:799-799.
      • Lüngen M, Rupprecht CJ, Plamper E, Lauterbach KW. Centralisation of breast cancer management by giving minimum work-load. Empirical effects in the region of North-Rhine, Germany. Z Arztl Fortbild Qualitatssich. 98(5). 2004:385-9.
      • Stoffel MP, Lauterbach KW, Baldamus CA. Guideline-based medical quality management in dialysis. Motivation and structuring of a quality-management system and integration of earlier disease stages of chronic renal failure. Z Arztl Fortbild Qualitatssich. 98(7). 2004:609-16.



      • Gandjour A, Lauterbach KW. The practice-makes-perfect hypothesis in the context of other production concepts in health care. Am J Med Qual. 18(4). 2003:171-5.
      • Gandjour A. Economic analysis of influenza vaccination and treatment. Ann Intern Med. 138(7). 2003:607-8. Gandjour A. Productivity loss due to irritable bowel syndrome. Arch Intern Med. 163(18). 2003:2249.
      • Weimar C, Weber C, Wagner M, Busse O, Haberl RL, Lauterbach KW, Diener HC. Management patterns and health care use after intracerebral hemorrhage. a cost-of-illness study from a societal perspective in Germany. Cerebrovasc Dis. 15(1-2). 2003:29-36.
      • Lauterbach KW. "Hard landing" due to inflexible fee system, but: "The market forces will increase quality in clinics". F&W compass comparison points to overmanagement of mild and undermanagement of severe cases. Chirurg. 74(2). 2003:M40.
      • Icks A, Rosenbauer J, Rathmann W, Haastert B, Gandjour A, Giani G. Direct costs of care in Germany for diabetic children and adolescents in the early course after onset. Diabetologia. 46 Suppl.. 2003:A442-A443.
      • Gandjour A, Neumann I, Lauterbach KW. Appropriateness of invasive cardiovascular interventions in German hospitals (2000-2001): an evaluation using the RAND appropriateness criteria. Eur J Cardiothorac Surg. 24(4). 2003:571-7. Gandjour A. Burden-of-disease estimates. Health Aff (Millwood).. 22(1). 2003:286.
      • Gandjour A, Lauterbach KW. Utilitarian theories reconsidered: common misconceptions, more recent developments, and health policy implications. Health Care Anal. 11(3). 2003:229-44.
      • Brunner H. Cost-containment by early, rapid and precise detection of etiologic agents using modern molecular diagnostics?. Int J Med Microbiol. 292(7-8). 2003:421-2.
      • Gandjour A, Lauterbach KW. Inductive reasoning in medicine: lessons from Carl Gustav Hempel's 'inductive-statistical' model. J Eval Clin Pract. 9(2). 2003:161-9. Lungen M, Lapsley I. The reform of hospital financing in Germany: an international solution?. J Health Organ Manag. 17(5). 2003:360-72.
      • Gandjour A, Lauterbach KW. An evidence-based disease-management program for patients with diabetic nephropathy. J Nephrol. 16(4). 2003:500-10.
      • Gandjour A. Depression and health-related quality of life. JAMA. 290(18). 2003:2404.
      • Gandjour A, Bannenberg A, Lauterbach KW. Threshold volumes associated with higher survival in health care: a systematic review. Med Care. 41(10). 2003:1129-41.
      • Gandjour A, Lauterbach KW. When is it worth introducing a quality improvement program? A mathematical model. Med Decis Making. 23(6). 2003:518-25.
      • Lauterbach KW, Lüngen M. DRG in the context of current health policy]. Med Klin (Munich). 98(8). 2003:467-71. Gandjour A. Lost in translation. N Engl J Med. 349(23). 2003:2273-4.
      • Gandjour A, Schlichtherle S, Neugebauer A, Rüssmann W, Lauterbach KW. A cost-effectiveness model of screening strategies for amblyopia and risk factors and its application in a german setting. Optom Vis Sci. 80(3). 2003:259-69.
      • Esser M, Brunner H. Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia. Pharmacoeconomics. 21(18). 2003:1295-313.
      • Lüngen M, Lauterbach KW. Prospective payment in medical rehabilitation. Rehabilitation (Stuttg). 42(3). 2003:136-42.
      • Lüngen M, Lauterbach KW. Relevance of medical rehabilitation in disease management programmes. Rehabilitation (Stuttg). 42(5). 2003:284-9.
      • Heindel W, Datené S, Lauterbach K, Gandjour A. Prospective observation of abdominal ultrasound in radiological emergency services: approaches to cost saving. Rofo. 175(9). 2003:1207-13.
      • Krug B, Boettge M, Reineke T, Coburger S, Zähringer M, Harnischmacher U, Lüngen M, Lauterbach KW, Lehmacher W, Lackner K. Quality control of outpatient imaging examinations in North Rhine-Westphalia, Part II. Rofo. 175(1). 2003:46-57.
      • Zahn R, Fraiture B, Siegler KE, Schneider S, Gitt AK, Seidl K, Gandjour A, Wendland G, Vogt S, Lauterbach KW, Senges J. Effectiveness of the glycoprotein IIb/IIIa antagonist abciximab during percutaneous coronary interventions (PCI) in clinical practice at a single high-volume center. Z Kardiol. 92(6). 2003:438-44.